Author:
Fehrenbach N.,Krähenbühl S.,Duthaler U.,Odermatt A.,Bouitbir J.
Subject
Toxicology,General Medicine
Reference6 articles.
1. “Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.”;Grandinetti;Pharmacotherapy,2007
2. “Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.”;Demetri;Lancet (London, England),2013
3. “Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials.”;Ghatalia;Critical reviews in oncology/hematology,2015
4. “Sunitinib induces hepatocyte mitochondrial damage and apoptosis in mice.”;Paech;Toxicology,2018
5. “SOD2 in mitochondrial dysfunction and neurodegeneration.”;Flynn;Free radical biology & medicine,2013